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Background: The burden of non- communicable diseases (NCDs) in low and middle -income 
countries is greatly increasing and posing both financial and public health concerns.  Increased 
morbidity has significantly reduced quality of life in these populations and Swaziland is no 
exception. Patients with NCD’s often have to pay for their medicines out-of-pocket. The extent 
of this practice is not known. 
Methods: The study was conducted at a regional hospital in Manzini that serves majority of 
NCD patients in the central part of the country. Exit interviews were conducted with 300 
patients diagnosed with diabetes, hypertension and asthma. Patients were asked how often 
they experienced stock-outs of essential medicines at the facility and how much they paid at 
private pharmacies to access the medicines.  Responses were triangulated with Central Medical 
Stores’ (CMS) 2012 annual stock records to ascertain availability of the selected medicines and 
their turnaround time which was the time taken for medicines to be issued to the facility on 
receipt after they had been out of stock at CMS. Results were analyzed using the Statistical 
Package for Social Sciences (SPSS). 
Results: Majority of patients (n=213; 71%) confirmed not receiving the complete package of 
their prescribed medicines at each visit to the hospital in the past six months. On average 
patients spent 10-50 times more for their medicines in private pharmacies than they would 
when accessing them from the health facility. Stock-outs at CMS ranged from minimum of 30 
days to over 217 days in the course of the assessment period (12 months) were recorded and 
found to be the cause of stock-outs in the health facility. The turnaround time of medicines 
from CMS to the facility was not found to have influence on shortages recorded in facility.  
Conclusion: Out-of-pocket expenditure is very common for patients with NCDs using this health 
facility which increases of the possibility of default on treatment because they cannot afford 
the commercial fees charged at private pharmacies. Patients were paying 10 to 50 times more 
to access medicines for their conditions in private pharmacies than when accessing them from 
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CHAPTER 1:  
1.1. INTRODUCTION 
Non communicable diseases are the leading cause of death and disability worldwide and their 
prevalence in low and middle income countries is on the rise (WHO, 2005). The burden of 
chronic health expenditure borne by patients may be very high particularly where out-of-
pocket payment is common (Murphy et al., 2013). High out-of-pocket medical spending 
comprises the overwhelming majority of medical spending in developing countries. According 
to Smith-Spangler et al. (2012) it is associated with impoverishment and decreased spending for 
other necessities including food. Other studies conducted in developing countries have 
suggested that individuals with diabetes often delay seeking medical care until complications 
develop leading to high medical spending (Smith-Spangler et al., 2012).  
Availability of essential medicines in Swaziland has been a challenge just as it has been for most 
developing countries. The National Pharmaceutical Policy (2011) highlights the shortage of 
medicines in public health facilities and calls for patient user fees to top up the purchase of 
medicines. Despite paying user fees in order to access health care, patients may still experience 
shortages of essential medicines (Bhojani et al., 2012).  Consequently, prescriptions may need 
to be filled by means of out-of-pocket payment by patients at private pharmacies. This is 
assumed to be the major challenge faced by patients who need full access to health care in 
Swaziland by this study. 
This study focused on the availability of essential medicines for the three selected chronic 
conditions at Raleigh Fitkin Memorial Hospital (RFMH) and the financial burden of patients in 
the event that their medicines were not available in the facility. Data collection focused on the 
availability of 10 essential medicines for three non-communicable chronic conditions; diabetes, 
hypertension and asthma at RFMH and the impact of out-of-pocket expenditure by patients. 
These three non-communicable diseases are among the top 5 (five) chronic conditions that 
increase the burden of illness in Swaziland. The other two conditions that contribute to the 
burden of illness in the country are HIV/AIDS and Tuberculosis (HMIS, 2010). 
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The first section of this chapter presents the background and context of the study including the 
geographic and population context. The next section discusses the study problem being 
addressed by the research questions as well as the research questions being investigated. Also 
presented are the objectives and aims of the study. Lastly, the final section of the chapter 
presents a brief outline of the study design and methods, the expected outcomes as well as the 
definition of terms as used in the aims and objective statements. A brief outline of the rest of 
the chapters is presented last and the summary ties all the sections of the chapter together at 
the end.  
 
1.2 BACKGROUND  
 
The United Nations projects further increases in NCDs as a result of increases in world 
population coupled with increase in the share of people surviving to the age of 60 years (UN, 
2011). Furthermore, the prevalence of NCDs will increase globally and in developing countries 
as a result of accelerated economic growth fuelled by globalization and urbanization. As low 
and middle income countries shift from agricultural economies to service based economies and 
urbanization takes center stage, a shift towards more sedentary lifestyles will emerge and NCDs 
will prevail (WEF, 2011).       
 
The devastating impact of NCDs are projected to result in long term macroeconomic effects on 
labor supply, capital accumulation and GDP worldwide but even more severe in developing 
countries (Mayer-Foulkes, 2011). The economic impacts in developing countries are estimated 
to range from US$ 3 billion for direct medical costs of obesity related diabetes, coronary heart 
disease, hypertension and stroke in China to US$72 billion for treatment and productivity losses 
due to these conditions in Brazil (Fuster & Kelly, 2010). Evidently, as participation in the labor 
markets is relatively low and unemployment rates very high in developing countries, these 
costs will be borne by the already weak health systems and subsequently by the patients 
leading to increase in burden of the diseases. As noted by the World Economic Forum (2011), 
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NCDs compromise future economic and human development because poverty and ill-health are 
often passed down from one generation to the next. 
   
In Swaziland, both communicable and non-communicable diseases continue to be a major 
challenge (SDHS, 2006/2007).  The death rate reports due to NCDs globally stood at 64% and 
those reported for the country were 41.4% for males and 45.5% among females under the age 
of 60 years in 2008 (WHO, 2010). This showed that there is a great need for the country to 
improve their focus on disease pattern of NCDs and develop interventions to manage them 
effectively in order to reduce the increasing population affected by these conditions. NCDs have 
received inadequate attention, given the serious double burden of disease that prevails in the 
country which is communicable diseases and HIV/AIDS (WHO, 2013). The situation has been 
worsened by the advent of HIV and AIDS, and rising incidence of TB (SDHS, 2006/2007).The 
burden of communicable diseases is similarly reflected in the leading causes of patient 
morbidity and mortality, with AIDS and TB together accounting for two-thirds of admissions and 
a third of deaths (SDHS, 2006/20007). NCDs are among the top 15 conditions that lead to 
hospital admissions and out- patient visits in health facilities in the country (SDHS, 2006/2007). 
While the Swaziland government is solely responsible for procurement and storage of essential 
medicines for the country’s public health facilities, this has not been without challenges. The 
Swaziland National Pharmaceutical Policy (SNPP) (2011) states that the current warehouse, 
which is about 3500 cubic meters can only accommodate 6 months’ supply of stock for 
facilities, resulting in an over burden to the existing inventory system and often stock-outs of 
pharmaceutical commodities due to inadequate storage area to maintain the desired months of 
stock for CMS. In addition, medicines are provided for free in all public health facilities in the 
country with standard user fees of E10 which is equivalent to US1.13 charged for consultation 
in hospitals and E5 which is equivalent to US0.56 charged in clinics. Not only can these charges 
present a barrier for access to services for the poor and unemployed but it poses a problem for 




1.3 PROBLEM STATEMENT 
Availability of medicines in low income countries to manage chronic conditions has been a 
challenge. Researchers have shown that there is an increase of non-communicable conditions 
in low income countries hence a need to improve the quality of life by making  medicines 
available at the point of care (National Commission on Prevention Priorities, 2007). In Swaziland 
there have been very few studies that assessed the availability of medicines to manage non-
communicable conditions in health facilities and none investigated the cost impact of out-of-
pocket spending by patients for medicines not available in public health facilities.  
1.4 AIM AND OBJECTIVES 
The aim of the study was to investigate the availability of medicines for non-communicable 
conditions in the health facility and the impact of out-of-pocket spending by patients for 
medicines not available in the facility. Specific objectives were; 
• To assess the availability of a basket of medicines for three selected non-communicable 
chronic conditions (Asthma, Diabetes and Hypertension) in the health facility. 
• To assess the average turnaround time (time taken for medicines to be issued to the 
health facility on receipt at CMS of the selected medicines at  CMS to the facility in the 
event it was out of stock. 
• To assess the cost impact of out-of-pocket expenditure by patients in the event their 
prescribed medicines were out-of- stock in the health facility. 
 
1.5 TYPE OF STUDY AND METHOD 
This was a cross sectional study that surveyed NCD patients that visited the health facility 
during the study period. A questionnaire was administered in an interview format by data 
collectors and responses were recorded. All respondents were assured of confidentiality and 




1.6 STUDY OUTCOMES 
The study outcomes  included identifying the root causes of frequent stock-outs of essential 
selected basket of medicines for treating the three NCD conditions at RFMH and establishing 
the financial  burden imposed to  patients when  buying the out of- stock medicines from 
private pharmacies.  
 
1.7 DEFINITION OF TERMS 
Non-Communicable Diseases: are defined as diseases of long duration, generally slow 
progression and they are the major cause of adult mortality and morbidity worldwide (WHO, 
2005a). 
Asthma: is a chronic lung disease that inflames and narrows the airways. It has clinical features 
including intermittent dyspnea, chest tightness ad coughing.  The coughing often occurs at 
night or early in the morning (NIH, 2012). 
Diabetes: is a metabolic disorder caused by defects in insulin secretion or insulin action or both. 
If ineffectively controlled, the resulting chronic hyperglycemia is associated with numerous 
complications (WEF, 2011). 
Hypertension: Hypertension, also known as high or raised blood pressure, is a condition that 
can lead to coronary heart disease, heart failure, stroke, and kidney failure. If blood pushes 
hard through the walls of the arteries as the heart pumps blood and the pressure remains high 
over time, it can damage the body. Blood pressure is measured through systolic and diastolic 
pressure (WHO, 2013). 
Out-of-pocket expenditure: refers to when people pay for their health costs directly to health 
care providers out of their own pockets (WHO, 2007). 
 
1.8 OUTLINE OF THE STUDY 
The main part of the thesis contains six major chapters. Each chapter is intended to link with 
the next and flow chronologically as per the process of conducting research. Chapter 2 contains 
a comprehensive review of related literature that is peer reviewed. Explicit definition of terms 
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and the theoretical frameworks that inform the study are also presented by their themes.  
Chapter 3 presents a detailed description of the methodology adopted in this study. The study 
setting, design and sampling procedures are explained in detail including the inclusion and 
exclusion criteria as well as ethical considerations. Also outlined in the chapter are the data 
analysis processes for each objective as well as the statistical software used for analysis. 
Chapter 4 presents the results of the analysis disaggregated by the demographics of the 
respondents. Also presented is the breakdown of responses per objective and graphical displays 
together with brief interpretation of the findings.  Chapter 5 focuses on discussion of the results 
and how they compare to other studies in the same area. The discussion follows the chapter 4 
results analysis and addresses each objective outlined in chapter 1. The last chapter, chapter 6, 
summarizes the study findings and answers the main study question. It presents the limitations, 
recommendations and significance of the study.   
1.9 SUMMARY 
This chapter has provided background information about NCDs from a global perspective as 
well as regional and Swaziland context. The problem statement, purpose of the study as well as 
the specific objectives has been explained. A brief outline of the study type and methods was 






CHAPTER 2: LITERATURE REVIEW 
 
2.1 INTRODUCTION 
This chapter presents the relevant literature that was reviewed based on local studies that have 
been conducted both in Swaziland and elsewhere in the world pertaining to NCDs and patient 
costs. The chapter begins with interrogation of global strategies and policy frameworks for 
availability of medicines in health facilities and then outlines specific findings from studies 
conducted world over but mainly in Africa.   The chapter concludes by relating the literature to 
the problem under investigation in order to put the current study into perspective and link it 
with existing body of knowledge and work performance. 
Universal Health Coverage 
The availability of essential medicines in public hospitals in universal health coverage has two 
important components. The first is the extent to which people are covered by the health 
services that they need.  The second is the degree of financial risk protection they have in using 
services – for example, do they suffer financially as a result of having to pay for the services 
they need (Xu et al., 2007).  It is estimated that over a billion people globally are unable to use 
the health services they need, while a 100 million people are pushed into poverty and 150 
million more face financial hardship because they have to pay directly for the health services 
they use at the point of delivery (Xu et al., 2007; WHO, 2010).   These statistics are a reflection 
of the challenges faced by poor patients in developing countries as they seek health care for 
their conditions. Evidently, they are further pushed into financial distress by their chronic 
conditions as they cannot afford to pay for medicines they need to manage their conditions. 
According to Hogerzeil et al. (1995) problems of irrational use of medicines and non-availability 
of medicines in the public sector are often similar in many countries. The non-availability of 
medicines in public health facilities is one of the contributing factors to catastrophic financial 
situations for most families who have relatives that need chronic treatment as they need to 
make provisions of making the medicines available by digging deeper into their pockets to 




Health Spending on Medicines 
Medicines account for 20–60% of health spending in developing and transitional countries, 
compared with 18% in countries of the Organization for Economic Co-operation and 
Development (Cameron et al., 2009). Up to 90% of the populations in developing countries 
purchase medicines through out-of-pocket payments, making medicines the largest family 
expenditure item after food. As a result, medicines are unaffordable for large sections of the 
global population and are a major burden on government budgets (Cameron et al., 2009). 
In studies conducted by Uplekar et al. (2001) and Gertler & Gruber (2002) it was found that 
disease and ill health does not only cause suffering and death but also have an important cost. 
They found that in most societies disease does not only create out-of-pocket expenditures for 
patients and their families, but also undermines income generation, and as a consequence 
jeopardizes future economic welfare.  
Furthermore, a study carried out in Cambodia looking at out-of-pocket health expenditure and 
debt in poor households found that patients who used only the public hospital paid US$8 for 
services provided to them (Van Damme et al., 2004). These households used a combination of 
savings, selling consumables, selling assets and borrowing money to finance their health 
expenditure. When followed up a year after the study, most families with initial debts were 
found to have been unable to settle these debts, and continued to pay high interest rates 
ranging between 2.5% and 15% per month. Consequently, several households had to sell their 
land to meet this expenditure which further increased poverty and shows the economic costs 
to patients of out-of-pocket health expenditures.  
Economic Impact of out-of-pocket expenditures 
While health economists  dedicated much effort to document the impact of user fees on access 
to health care in developing countries as early as the 1990s there was little attention given to 
the impact of out-of- pocket health expenditure on welfare (Gilson et al., 2002). Recent 
developments however has put this in the global research agenda and the first attempt by 
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WHO to estimate the importance of catastrophic health expenditure was recorded in 2000 (Xu 
et al., 2003; Whitehead et al., 2001). In developing countries, more focus has been put on 
communicable and transmittable diseases and patient access to healthcare has been increased 
because of the removal of user fees at the point of care. If removal of user fees has worked 
quite well for conditions like TB, HIV/AIDS and STI’s to achieve health goals, then policy 
developers should look into how best they can achieve the same goal with NCDs in these poor 
countries. 
Findings from a study that was carried out in India – Delhi, showed that prior to 1994 most 
Delhi hospitals and dispensaries experienced constant shortages of medicines (Chaudhury et 
al., 2005). A number of factors contributed to this drug shortages including erratic prescribing 
of expensive branded products, complaints on poor drug quality and low patient satisfaction 
(Chaudhury et al., 2005). Since 1994, in hospitals run by the Government of Delhi, the Essential 
Drugs Programme has provided good quality medicines to patients. Establishing and using a 
limited list of carefully selected essential drugs was the cornerstone to improving drug supply 
management (Chaudhury et al., 2005).  
Swaziland public expenditure on medicines has generally remained low at about US$1 per 
capita which is equivalent to E8.88. Patients largely depend on out-of-pocket expenditure by 
purchasing from chemists (retail pharmacies) and private practitioners (SNPP, 2011). The policy 
also conceded that while nearly three quarters of health care, including medicines, is obtained 
from private sources, underprivileged populations, often living in remote rural areas, depend 
largely on public facilities. A study carried out in Laos found that out-of-pocket payments made 
up about 80% of medical care spending at hospitals in Laos, thereby putting poor households at 
risk of catastrophic health expenditure (Syhakhang et al., 2011). As a result, it was found that 
the increasing out-of-pocket expenditures in public and private health care services are driving 
many families into poverty, and are further burdening those who are already poor (Syhakhang 
et al., 2011). In addition, in order to gain access to public hospitals and to receive a higher 
quality of services, in some countries; informal payments are widespread and are a major 




Another study carried out in Kenya investigating major failures to provide access to effective 
treatment of malaria, found that a key benchmark of successful therapeutic policy 
implementation and effectiveness is ensuring that recommended or prescribed medicines are 
available at the point of care (Kangwana et al., 2009). Furthermore, a review study carried out 
in selected low and middle income countries by McIntyre et al. (2006), found that the reasons 
for the high frequency of medicine stock outs varied and reflected perennial problems facing 
weak health systems in resource poor countries. This study also showed that the impact of 
direct and indirect costs of medicines continued to impoverish households through out-of-
pocket payment for medicines.  They also noted growing evidence of households being pushed 
into poverty or forced into deeper poverty when faced with substantial medicine expenses 
especially when combined with loss of household income due to ill health (McIntyre. et al., 
2006). This situation is experienced by most families in developing countries which further 
impacts on the economic growth of a country. 
Another study carried out by WHO looking at how families were coping with out-of-pocket 
health payments established empirical evidence that in the short run, when medical bills 
exceed a household’s income, households may use savings, sell assets, borrow money from 
friends and family, or take out a loan using collateral (Leive et al., 2008). Families may also alter 
their labor allocation decisions; if a household head falls ill, family members previously not 
working may begin to do so to substitute for lost income and repay loans (Leive et al., 2008). 
The study show a great need for improving availability of essential medicines at the point of 
care in developing countries for all conditions inclusive of NCDs.  
Diabetes as a Case Study 
Individuals with diabetes in developing countries delay seeking medical care until they have 
developed complications which lead to further high medical spending because they do not have 
enough funds to pay when accessing healthcare therefore delaying to seek health care whilst 
increasing the complication of their condition and making it more expensive to treat (Smith-
Spangler et al., 2011). A study carried out in the U.S. on problems of paying out-of-pocket for 
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medication costs among older adults with diabetes, found that many adults under-used their 
medication because of out-of-pocket costs (Piette et al., 2004). The study interviewed 875 
adults with diabetes and treated with diabetes medication and 19% (n=167) reported that they 
had underused prescription medications because of cost pressures.  
 
Also, respondents were asked to describe their interactions with clinicians about medication 
costs. Only 32% of respondents who reported cutting back on medication use due to out-of-
pocket costs reported telling a doctor or nurse in advance, and more than one in three (37%) 
reported never talking with clinicians about their medication cost problem at all. The most 
common reason that respondents gave for not talking with clinicians about medication cost 
problems was that clinicians never asked them. About half (50%) of respondents who did not 
talk with clinicians about their cost-related adherence problems stated that they did not think 
that their health care providers could help them with medication costs, 39% did not think it was 
important enough to mention it, and 35% indicated that they felt embarrassed. A total of 30% 
of respondents indicated that they felt that there was insufficient time during their visits to 
raise this issue (Piette et al., 2004). 
The results of the study showed that medication costs posed significant problems for people 
with diabetes in the U.S., affecting both their adherence to medication regimens as well as 
other aspects of their lives. Moreover, the study suggested that there is substantial room for 
improvement in clinicians’ and health systems’ efforts to assist patients with their medication 
costs (Piette et al., 2004). Addressing these issues effectively may improve not only individuals’ 
adherence to treatment regimens but their health outcomes as well (Piette et al., 2004). 
 
2.2 SUMMARY 
This chapter provided a comprehensive review of studies conducted on non-communicable 
diseases and patient out-of-pocket health care expenditures world over. The themes to be 
assessed by this study were clearly articulated and included challenges in universal health 
coverage, health spending gaps especially as they relate to ensuring uninterrupted supply of 
20 
 
essential medicines as well as coping strategies adopted by health systems in developing 
countries and how they impact the access to care for the poorest in these countries. The 
chapter also discussed the literature findings on how much of health care costs are borne by 
patients in developing countries when availability of essential medicines in the health system is 




CHAPTER 3: METHODOLOGY 
 
3.1 INTRODUCTION 
This chapter presents a detailed description of the research methodology. It outlines the 
detailed procedure that was followed to realize the research objectives.  The first section 
addresses the study design, setting and sampling procedure. The last sections describe the data 
collection methods, data analysis and ethical considerations.  
 
3.2 STUDY DESIGN 
The study was a prospective cross-sectional survey that measured the cost burden incurred by 
patients on chronic medication for asthma, diabetes and hypertensive treatment in the event 
that their prescribed medicines were out of stock at RFMH, Manzini.  
 
3.3 STUDY AREA 
The study took place at RFMH, a 350 bed regional referral hospital situated in Manzini, the hub 
of Swaziland. The hospital is a referral for all hospitals, clinics and health centers in the Manzini 
region. The hospital attends to an average of approximately 200 000 patients per year which is 
approximately 20% of the country’s population. Approximately 40% of patients seen at RFMH 
have asthma, diabetes and hypertension conditions. The number of out-patients that receive 
medications in the Pharmacy stands at an average of 750 patients a day. An average of 200 
patients is admitted into the hospital wards for different conditions including both 
communicable and non-communicable diseases which accounts for an average of 57% bed 
occupancy at any given time (RFMH, 2012).  
More than 50% of in-patients also receive their prescribed medicines from the pharmacy on a 
daily basis. The hospital has recently been upgraded to having an Intensive Care Unit and a 
Renal Unit which is the second hospital providing this service after Mbabane Government 




The hospital has 23 general practitioners and 8 Specialists which includes 2 gynecologists, 1 
pediatrician, 1 internist, 1 orthopedic surgeon, 1 general surgeon and 2 anesthesiologists1. The 
hospital is situated at a radius of 7 kilometers away from CMS which is the supplier for 
medicines and medical supplies in the country. The hospital uses its own transport to collect its 
orders for medicines from CMS. It sometimes requests the assistance of CMS transport when 
the facility itself has transport shortages.  
CMS is the main pharmaceutical warehouse mandated to manage the supply chain of medicinal 
commodities in the country. The current warehouse is approximately 3500 cubic meters and 
can only accommodate 6 month supply for facilities (SNPP, 2011). Procurement of medicines 
and medical supplies is managed by the recently established procurement unit within the CMS. 
In principle, procurement is restricted to medicines and medical supplies listed in the country’s 
National Essential Medicines List (NEML). Procurement of medicines and medical supplies is 
done through the open tender system whereby the procurement unit advertises the tender on 
the local newspaper and the government website. Bidding companies submit their bidding 
documents to the MOH and the National Medicines Advisory Committee is responsible for the 
evaluation of the tender which is then approved by the National Tender Board usually awarded 
as one year contracts (SNPP, 2011). 
CMS currently have four pharmacists who are responsible for the functioning of the 
organization and hold different responsibilities in the different units of the organization. CMS 
has a schedule for filling out health facilities requisition orders. Orders from facilities are 
processed by pharmacy technicians, assisted by the clerks and verified by store keepers. Each 
region is allocated one week for processing and delivering of their orders. CMS uses its own 
transport to deliver orders for clinics and health centers. Hospitals collect their orders from 
CMS when these are ready for collection. Orders from facilities have a lead time of two weeks 
for processing after placement of an order by a facility. Facilities are immediately informed by 
                                                          
1
 Personal Communication: Human Resources Offices of Raleigh Fitkin Memorial Hospital, March 2013 
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the warehouse pharmacists when a product that has been out of stock has arrived to place 
their orders immediately and these orders are treated as emergency orders2. 
The system that is currently used by CMS for inventory control is called an Rx solution that is 
provided by Management Sciences of Health (MSH), a Non- Governmental Organization in 
support of the MOH to strengthen the pharmaceutical sector. Internal orders are generated 
based on the quantities available on hand at Central Medical Stores. This is verified by doing 
physical checks and through the inventory system.  MOH is currently working on strengthening 
this unit by making it autonomous and also improving its organizational structure3. 
 
3.4 STUDY POPULATION  
The study population comprised of all patients who were seen for the three chronic conditions 
(diabetes, asthma and hypertension) per month in the facility. The hospital was seeing on 
average a total of 2,778 in-patients and out-patients per month and 40% of the patients seen 
accounted for the three conditions. On average, a total of 1,111 patients were consulted for 
asthma, diabetes and hypertension at RFMHl per month4.  
 
3.5 STUDY SAMPLE AND SIZE 
The statistical formula below (Machin &Cambell, 1987) was used to calculate the number of 
patients to be interviewed based on the monthly statistics of the hospital. 
 n = N/[1 + (Ne2)]     
Where n is the sample size, N is the target population and e is the accepted level of error taken 
at α of 0.05. 
Calculation: 
n = 1100/[1 + (1100*0.052)] 
                                                          
2
 Personal Communication: Senior Pharmacist at Central Medical Stores, March 2013 
3
 Personal Communication: Senior Pharmacist at Central Medical Stores, March 2013 
4
 Personal Communication: Statistics Office of the Raleigh Fitkin Memorial Hospital, March 2013  
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n = 293 (300 patients were selected) 
Based on the calculation, a sample of three hundred patients with the chronic conditions 
(diabetes, hypertension and asthma) were selected at their point of exit which was the 
pharmacy and interviewed using a questionnaire. 
 
3.6 INCLUSION AND EXCLUSION CRITERIA 
The following inclusion/exclusion criteria were applied in selecting patients for the study 
             
 3.6.1 INCLUSION CRITERIA 
 Patients who had asthma, diabetes or hypertension. 
 Patients who had been diagnosed with their conditions for more than 6 months. 
 Patients who were refilling their medications at RFM hospital. 
 Patients who made their refill visit to the hospital during the study period. 
 Patients who were 18 years and above. 
 Both female and male patients were recruited into the study. 
 
3.6.2 EXCLUSION CRITERIA 
 Patients who were not diagnosed with asthma, diabetes and hypertension. 
 Patients who had been diagnosed for less than 6 months with asthma, diabetes and 
hypertension. 
 Patients less than 18 years old. 
 Patients who came to the facility as emergency cases and do not do their monthly refills 
for their conditions in the hospital. 
 
3.7 DATA COLLECTION INSTRUMENT 
A quantitative coded questionnaire (with some open ended questions) was used for the exit 
interviews with patients that fulfilled the inclusion criterion. The questionnaire was divided into 
three sections; the demographics section including patients’ employment status, a section on 
patients’ experiences of stock outs of medicines and a section on costs of buying the medicines 
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out-of-pocket. Both SiSwati and English versions of the questionnaires were availed to allow 
patients to choose their preferred language of interview.  At CMS, stock status data for the ten 
selected basket of medicines was used to check the availability of the medicines and the time it 
took to be available at RFMH after receipt when it was out of stock for the period July 2012 to 
June 2013.  
 
3.8 PILOT STUDY 
Pre-testing of the questionnaire was conducted on 10 patients by the data collectors. Prior to 
pre-testing a one day training was done for the data collectors on how to administer the 
questionnaire to patients as well as controlling for any bias in the sampling procedure thereof. 
The pharmacy staff that was to select the patients based on prescription data was also part of 
the training. After pre-testing the questionnaires were revised to increase usability and address 
any ambiguous questions that were noted during interviews with hospital staff.    
 
3.9 DATA COLLECTION 
Data was collected from patients who had come to collect their medicines from the pharmacy 
through exit interviews. The interviews were done to patients at their exit point which is the 
Pharmacy at RFMH. The interviews were done by two, second-year Pharmacy students from 
the Southern Africa Nazarene University after the prescriptions were pre-selected by the 
Pharmacy Technicians and Pharmacists dispensing their prescription. The selection by the 
professional staff was based on the diagnosis of the patient. The data collectors randomly 
selected by administering the questionnaire to every third patient encounter based on age, 
residence and diagnosis of the patient as appearing on the prescription.  
The data collection was carried out over a period of six weeks from August 23, 2013 to October 
4, 2013. The questionnaire was used to; (i) determine if patients had been exposed to out of 
stock of medicines for their chronic conditions in this facility, (ii) establish the coping strategies 
they were using in order to access their medicines in the event they were out of stock in the 
facility, (iii) identify the consequences of the unavailability of medicines in the facility to 
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patients and their immediate families, (iv) establish the affordability or lack thereof, of 
purchasing medicines out-of-pocket and any complications or misadventures they have 
experienced due to out of stock of medicines in the facility. 
Data collection at CMS was done through the Senior Pharmacist who provided the stock status 
records for the selected medicines from July 2012 to June 2013. The records were used to 
calculate the number of days each medicine was out of stock at CMS and how soon it was made 
available to RFMH after the date of receipt.  
 
3.10 DATA MANAGEMENT 
All the data collected and the completed questionnaires were stored in a locked cupboard in 
the researchers’ private abode and no access was given to anyone except for the data collectors 
who helped capture the data into SPSS. For confidentiality purposes, the hospital staffs who 
were involved in selection of patients into the study had no access to the completed 
questionnaires and responses of the patients. The questionnaires will remain locked safely for 
the next three years after which they will be destroyed in accordance with the Data 
Management Policy of the Ministry of Health.   
 
 
3.11 DATA ANALYSIS 
Two open ended questions in the questionnaires were collated after data collection for ease of 
entry into the database. Data was categorized, coded and entered first into an excel spread 
sheet and later imported into SPSS where descriptive statistical analysis was conducted (A 
sample of the excel database is attached as annex 3).  Frequency tables were generated by 
objective and formed the basis of the study findings.  Cross tabulations were used for bivariate 
analysis and to test for any significant correlations between some data variables. Regression 




The data analysis followed the core sections of the questionnaire as they related to the study 
question and objectives. The analysis was divided into five sections; Demographic information, 
Socio-Economic Status, Health Status, Availability of Medicines and Doctor-Patient 
Relationships.  
 
3.12 RELIABILITY AND VALIDITY 
To increase validity of the data collected, the data collection questionnaires were shared with 
experts in health services research at the University of KwaZulu-Natal for review before data 
collection took place. This helped improve the questions that were to be posed to study 
respondents to avoid ambiguity. Also reliability was increased by ensuring that all respondents 
were asked the same questions designed in the same format and at the same setting thereby 
reducing interviewer bias and ensuring that if a different cohort of patients who shared similar 
attributes as those selected into this study were to be interviewed with the same questionnaire 
the same results would be observed.  
 
3.13 ETHICAL CONSIDERATIONS 
Ethical clearance to perform the study was obtained from University of KwaZulu-Natal 
Humanities and Social Sciences Research Ethics Committee and the Ministry of Heath Ethics 
Committee in Swaziland (See Attached Annexure 6 for sample of Approval Letters). 
 
3.14 SUMMARY  
This chapter was a description of the methodology that was used for the study. It focused on 
research design, description of the study population, sampling and sampling procedure, 






CHAPTER 4: RESULTS 
 
4.1 INTRODUCTION 
This chapter presents the findings from the study together with a detailed data interpretation. 
First to be presented is the analysis of the demographic data of the respondents to understand 
their characteristics. This analysis focused on age, gender, level of education, marital status, 
occupation, religion, and income distribution. The next sections present findings per objective 
and the interpretation of tables and figures.   
 
4.2 RESULTS 
A total of 300 patients participated in the study over a 6 weeks period. Demographic data will 















4.3 DEMOGRAPHIC INFORMATION 
Table 1: Demographic Characteristics of Respondents 
 
n= 300 
E = Swaziland Lilangeni 
  
Variables Frequency 
                                          
Percentage 
Age 
  18 - 24 10 3.3 
25 - 34 27 9 
35 - 49 65 21.7 
50 - 64 128 42.7 
65+  70 23.3 
Gender 
  Male  85 28.3 
Female 215 71.7 
Educational Level 
  Primary 96 32 
Secondary 102 34 
Tertiary 51 17 
Never 51 17 
Marital Status 
  Single 66 22 
Married 154 51.3 
Divorced 7 2.3 
Widowed 73 24.4 
Occupation 
  Unemployed 118 39.3 
Employed 75 25 
Self - Employed 68 22.7 
Pensioned 39 13 
Religion 
  Christian 294 98 
Muslim 3 1 
Other 3 1 
Area of Residence 
  Urban 66 22 
Semi - Urban  60 20 
Rural 174 58 
 Income Distribution 
  ≤ E500 133 44.3 
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E501 - E1000 67 22.3 
E1001 - E2000 48 16 
E2001 - E5000 23 7.7 
˃ E5000 29 9.7 
 
Table 1 indicates the distribution of the patients interviewed according to demographic 
distribution. The highest age group presenting for the three non-communicable conditions was 
50-64 years of age (n=128; 42.7%). There were very few patients below 34 years of age (n=37; 
12.3%) that presented with the selected NCD’s. Majority of patients with chronic conditions 
were females (n=215; 71.7%). Results showed that majority of the patients (n=249; 83%) had 
received some form of education but only a few among these (n=51; 17%) had reached tertiary 
education. The rest (n=51; 17%) had never been to school. Majority of the patients were 
married (n=154; 51.3%). 
 
The rate of unemployment among these patients was very high (n=118; 39.3%) with employed 
patients accounting for only 25% (n=75) and self-employed accounting for 22.7% (n=68).  
Almost all of the patients interviewed were Christians (n=294; 98%) and Muslims and others 
religions accounted for 1% (n=3) each respectively.   
 
According to the results, a majority (n= 174; 58%) of the patients were residing in the rural 
areas, while 20% (n= 60) and 22% (n=66) resided in semi-urban and urban areas respectively.   
Results on income distribution showed that 44.3% (n=133) of the interviewed patients had a 
monthly income of less than E500 which is equivalent to less than USD 50. At least 22.3% (n=67) 
of the patients had a monthly income between E501 to E1000 which is equivalent to less than 
between USD 50 – USD 100 while 16% (n=48) of the patients had a monthly income of between 
E1001 to E2000 which is equivalent to less than between USD100 – USD 200, and 7.7% (n=23) 
had a monthly income of between E2001 and E5000 which is equivalent to less than between 
USD 200 and USD 500. Only 9.7% (n=29) of the patients had an income of above E5000 which is 
equivalent to less than USD 500 according to the Central Bank of Swaziland Exchange Rate of 





4.4 HEALTH STATUS AND HEALTH SEEKING BEHAVIOR 
Table 2: Health Status and Health Seeking Behavior of Patients (n=300) 
Variables Frequency Percentage 
Health Conditions 
  Hypertension 118 39.7 
Asthma 59 19.7 
Diabetes 123 41 
Length  of time since diagnosis 
  6 months - 1 year 47 15.7 
1 year - 2 years 48 16 
˃ 2 years 205 68.3 
Frequency of refill visits 
  Every month 243 81 
Once in two months 9 3 
Only when feeling sick 48 16 
Reasons for missed monthly refills 
  Transport money to facility 21 38.2 
See no reason to come every month 16 29.1 
No one told me to come every month 11 20 
No money for paying for consultation  7 12.7 
 
Table 2 shows results of the health conditions of patients. Most of the patients involved in the 
study were hypertensive and diabetic. Diabetes accounted for41% (n=123), hypertension 39.7% 
(n=118) and 19.7% (n=59) had asthma.  Most of the patients had been diagnosed with their 
conditions for more than two years (n=205; 68.3%) and the rest were diagnosed with their 
conditions for less than two years. Most of the patients came for their refills on a monthly basis 
for their conditions (n=243; 81%). Only 3% (n=9) came once in two months and 16% (n=48) only 
when feeling sick. Patients who failed to come on a monthly basis for their refills were asked 
reasons for failing to adhere to their appointments. Of these, 38.2% (n=21) said they did not 
come because they did not have money for transport to the facility, 29.1% (n=16) said they did 
not find it necessary to do refills on a monthly basis, while 20% (n=11) said they were not 
informed that they were supposed to come to the hospital on a monthly basis and 12.7% (n=7) 
said they did not have money to pay for consultation (user fees). 
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4.5 AVAILABILITY OF MEDICINES 
Table 3: Availability of prescribed medicines in the facility (n=300) 
Variables Frequencies    Percentage 
Yes  74 24.7 
No  24 8 
Sometimes 189 63 
Don’t Know 13 4.3 
Frequency of not receiving prescribed medicines in the past six months 
Once  94 31.3 
Twice 29 9.7 
More than three times 29 9.7 
Not Sure 148 49.3 
 
Received all prescribed medicines on the day of interview 
Yes  237 79 
No 50 16.7 
Not Sure 13 4.3 
 
Proportion of prescribed medicines received 
None (0% - 50%) 25 8.3 
Partly (51% - 80%) 12 4 
Mostly (81% - 99%) 26 8.7 
Completely (100%) 237 79 
Instruction conveyed by dispensing personnel for medicines not available in the facility 
Return to doctor 18 6 
Referred to the chemist 
 282 94 
Turnaround time for buying medicines at the chemist 
  As soon as I leave the facility 119 39.7 
Whenever, after getting money 152 50.7 
When I go to town as there is no chemist in the community 8 2.7 
When I get paid 11 3.7 







Out-of-pocket expenditure by patients in private pharmacies 
˂ E100 191 63.9 
Between E100 - E300 86 28.8 
Between E301 - E500 7 2.3 
˃ E500 15 5 
Availability of health insurance cover 
  Yes  15 5 
No 285 95 
Health Insurance Cost Incurred 
  ˂ E1000 5 1.7 
˃ E1000 4 1.3 
Not Sure, paid by spouse 6 2 
N/A 285 94.7 
Declined to answer 1 0.3 
 
Number of family members supported 
 1 82 27.3 
2 37 12.3 
3 18 6 
˃ 5 27 9 
None 136 45.3 
Respondents comments on costs of medication and access to care 
Government should remove user fees to 
improve access to health care services 55 18.3 
Government should reduce user fees to 
improve access to health care services 66 22 
Government should standardize price of 
medicines in private pharmacies to 
increase affordability 86 28.7 
Government should provide health 
insurance for the elderly, unemployed 
and disabled 40 13.3 
No comment 53 17 
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The results in table 3 illustrate the availability of medicines in the dispensary of the facility. The 
interviewed patients were asked if they received all their prescribed medicines in the health 
facility. Only 24.7% (n=74) of the interviewed patients said they always got all their prescribed 
medicines in the hospital’s dispensary. Further analysis of the 24.7% (n=74) showed that 13.5% 
(n=10) were asthma patients, 48.6% (n=36) were diabetes patients and 37.8% (n=28) were 
hypertensive patients.  About 63% (n=189) of them said that sometimes they would get their 
full prescription and 8% (n=24) said that every time they came to the facility they did not get 
their full prescribed medications and 4.3% (n=13) were not sure if they had always got their 
fully prescribed medicines or not in the past six months. 
 
On availability of all prescribed medicines on the day of interview in the facility, 79% (n= 237) of 
the patients reported to have received all their prescribed medication on the day they were 
interviewed. On further analysis, it was noted that of the 79% patients who had received all 
their prescribed medicines on the day of interview, 13% (n=30) were asthma patients, 48% 
(n=114) were diabetic patients and 39% (n=93) were hypertensive patients.  However, 16.7% 
(n=50) of the patients did not receive all their prescribed medicines on the day they were 
interviewed and 4.3% (n=13) of the patients were not sure if they had received all their 
prescribed medicines or not. 
 
Further analysis was done to determine medicines available versus those prescribed on the day 
of interview. On this, 8.3% (n=25) received 0% - 50% of their prescribed medicines on the day of 
interview while 4% (n=12) of the patients received between 51% and 80% of their prescribed 
medicines and another 8.7% (n=26) had received between 81% – 99% of their prescribed 
medicines. A majority (n=237; 79%) of the patients received 100% of their prescribed medicines 






Patients were asked on the instruction given to them by the dispensing personnel in the event 
their medication was not available in the dispensary and 6% (n=18) said that they were referred 
back to the doctor or prescribing practitioner for changing of medicine not available and 94% 
(n=282) of the patients said that in the event their prescribed medicines were not available they 
were referred to the retail pharmacies to buy their medications. 
 
The length of time patients took to obtain their medicines when not available in the facility was 
analyzed. The results showed that 39.7% (n=119) of the patients said that they bought their 
medicines as soon as they left the facility, 50.7% (n=152) of the patients said that they bought 
their prescription medicines when they got funds to buy their medicines while 2.7% (n=8) said 
that they bought their medicines when they had access to a retail pharmacy because of their 
proximity to access a retail pharmacy. About 3.7% (n=11) said that they bought their medicines 
when they received their monthly pay and 3.3% (n=10) said that they only bought their 
medicines when feeling sick. 
 
The table also shows results of the cost to the patients’ when they bought the medicines out-
of-pocket at the chemist. About 63.9% (n=191) said that they were paying less than E100 which 
is equivalent to less than USD10 for their medication in the chemists, 28.8% (n=86) of the 
patients said that they were paying between E100 – E300 which is equivalent to less than 
between USD10 – USD30 while 2.3% (n=7) of the patients said that they were paying between 
E301 – E500 for their medication in a retail pharmacy which is equivalent to less than between 
USD 30 – USD 50 and 5% (n=15) were paying more than E500 which is equivalent to less than 
USD50 when buying their medication out-of-pocket in the event it was out of stock in the 
facility. 
 
 Only 5% (n=15) of the interviewed population had a private health insurance that they were 
using to buy medicines in a chemist in the event they were out of stock in the facility while 95% 
(n=285) of the patients did not have a health insurance and had to pay for their medicines out-
of-pocket in the event they were not available in the facility. 
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The cost of the health insurance patients were paying per month for their health insurance 
cover varied. About 1.7% (n=5) of the patients who had a health insurance were paying less 
than E1000 which is equivalent to less than USD 100 a month for their health insurance, 1.3% 
(n=4) of the patients who had a health insurance were paying more than E1000 which is 
equivalent to less than USD100 per month for their insurance; 2% (n=6) of these patients were 
not sure on how much they were paying for their health insurance as it was paid by their 
spouse and 0.3% (n=1) of the patients declined to give an answer about payment of their health 
insurance. 
The results of patients who had other family members for whom they were buying medicines 
out-of-pocket (other than their own medicines) were presented. About 27.3% (n=82) of the 
patients said that they had an extra person in their family they were buying medicines for other 
than their own medicines, 12.3% (n=37) of the patients said that they had other two family 
members they were buying medicines for out-of-pocket while 6% (n=18) of the interviewed 
population said that they had three members in their family they were buying medicines out-
of-pocket other than themselves and 9% (n=27) of the patients said that they had more than 
five members of their family members that they were buying medicines for out-of-pocket. 
About 45.3% (n=136) of the interviewed patients said that they had no other family members 
they were buying medicines for out-of-pocket other than themselves. 
 
Table 3 also illustrates results of patients’ views on availability of medicines in public health 
facilities. About 18.3% (n=55) of the patients felt that the government should remove user fees 
in order to increase access to healthcare services in public health facilities, 22% (n=66) of the 
patients felt that government should reduce user fees in order to increase access to healthcare 
services in public health facilities; 28.7% (n=86) of the patients said that the government should 
work around standardizing the prices of medicines in private pharmacies in order to increase 
affordability of medicines even in retail pharmacies, 13.3% (n=40) of the patients said that the 
government should provide healthcare insurance to the elderly, disabled and unemployed in 
order to increase access to healthcare services. The rest (n=53; 17.7%) of the patients declined 






4.6 DOCTOR-PATIENT RELATIONSHIPS 
Table 4: Patient- Doctor or Health Personnel communication (n=300) 
Variables Frequency  Percentage 
Responses on receiving counseling on treatment  adherence from health personnel 
Yes  294 98 
No  6 2 
Responses on hospitalization due to their health conditions 
Yes  50 16.7 
No  250 83.3 
Length of hospitalization  
  ˂ 3 days 39 78 
˃ 3 days 11 22 
Responses to whether they had ever missed review  appointments due to lack of funds 
Yes  102 34 
No  198 66 
Responses to whether they had communicated to health personnel that they cannot 
afford to buy medication on their own 
Yes  112 37.3 
No, I thought there is nothing he/she can do 121 40.3 
No, I felt it will embarrass me 17 5.7 
No, I felt it was unnecessary 50 16.7 
 
Table 4 shows results of communication by health personnel to the patients about the 
importance of medicines compliance. About 98% (n=294) of the patients said that the health 
personnel had explained the importance of medicine compliance for their conditions. Two 
percent (n=6) of the patients said that the health personnel had not explained or talked to 




Patients were asked if they were ever hospitalized because of their conditions in the past six 
months. About16.7% (n=50) of the patients said that they were once hospitalized in the past six 
months because of their conditions while 83.3% (n=250) of the patients had not been 
hospitalized. 
They were further asked about the number of days they spent in hospital. Of the 16.7% patients 
that were hospitalized, 78% (n=39) said that they were hospitalized for less than 3 days and 
22% (n=11) of them said that they were hospitalized for more than 3 days. The table also shows 
results of patients who failed to meet their appointments because of lack of funds. About 34% 
(n=102) of the interviewed patients admitted to have missed their appointments due to lack of 
funds and 66% (n=198) of the patients had never missed their appointments due to lack of 
funds. 
Patients’ communication with health personnel about not being able afford to buy their 
medicines out-of-pocket was analyzed. About 37.3% (n=112) of the patients said that they 
explained to the health personnel about not being able to buy their medicines out-of-pocket. 
About 40.3% (n=121) of the patients said that they did not talk to the health personnel about 
medicines affordability because they felt there was nothing the health personnel could do for 
them. About 5.7% (n=17) of the patients said they felt that this will embarrass them and 16.7% 
(n=50) of the patients said that they did not find it necessary. 
 
 4.7 STOCK AVAILABILITY AT CENTRAL MEDICAL STORES (CMS) 
Data of availability of ten essential medicines used to treat the three non-communicable 
diseases from CMS was collected using a data sheet whereby records of availability of the 
medicines were recorded for July 2012 to June 2013. These records were showing availability of 
medicines at CMS, days of stock-outs, date of receipts from suppliers and date of issues to 
RFMH. This data informed the study on how often medicines were out of stock at CMS which is 
the source of medicines supply for the facility and to confirm the information provided by 
patients on medicines availability in the facility. 
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Figure 1: Number of days the selected medicines was out of stock at CMS between July 2012 




The results in figure 1 shows that Captopril 25mg tablets which is used to treat hypertension 
was out of stock at CMS for 34 days in a period of 12 months . Hydrochlorothiazide 25mg tablet 
which is used for treating hypertension was out of stock for 217 days at CMS. Enalapril 20mg 
tablet, which is also used to treat hypertension, was out of stock for 59days in 12 months. 
Nifedipine 20mg Slow Release tablets also used in treating hypertension was also out of stock 
for 188 days. Glibenclamide 5mg tablet used to treat diabetes in patients was out of stock for 
81 days in twelve months at CMS. Metformin 500mg tablet which is also used in diabetes 
treatment was out of stock for 47 days and Actraphane insulin which is also used to treat 
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Salbutamol 4 mg tablet which is used to treat asthma was out of stock for 146 days. Salbutamol 
spray which also used by asthma patients for management of their asthma condition was out of 
stock for 57 days. Beclomethasone spray which is also used for asthma management was out of 
stock at CMS for a period of 81 days in a 12 months period. 
In general, hypertensive medications were less available in the 12 months review period as 
their days out of stock ranged between 34 days and 217 days with average mean of 124.5 days 
followed by asthma medication which ranged 57 days and 146 days with an average mean of 
94.67 days and diabetes medication were the most available as their days out of stock ranged 
between 21 days and 81 days with an average mean of 51.3 days. 
 
Table 5: Summary of Descriptive Analysis of Days for out-of-stock medicines at CMS 
 
The table shows that the overall mean of days out of stock for the selected medicines from CMS 
was 93.6 days which was more than three months in a period of one year. The median was 70 
days and standard deviation was 66.7days. In 90% of the medicines that were out stock at CMS, 
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the gap of days occurred once. Only 10% of the medicines had an occurrence of two times in a 
period of 12 months. 
 
Figure 1 also shows results on how soon medicines were issued to RFM hospital on receipt from 
suppliers at CMS. A majority n=7 (70%) of the medicines were issued within a period of 1 day 
and 11 days  on receipt at CMS to the health facility.  The list of medicines are Beclomethasone 
spray, Enalapril 20mg, Insulin Actraphane, Captopril 25mg, Metformin 500mg and Nifedipine SR 
20mg tablets. Salbutamol spray was issued in 33 days after receipt. Glibenclamide was issued in 
44 days after receipt. Both these medicines were issued to the facility above the stipulated lead 
time of two weeks.  Data on Hydrochlorothiazide 25mg tablets was unavailable at the time of 
the data collection hence one could not gather whether this medicine was issued to the health 
facility on receipt at i CMS. Based on these findings, most medicines (70%) were issued within 2 
weeks of receipt to RFMH by CMS which is the lead time stipulated in Pharmaceutical Standard 
Operational Procedures for ordering of medicines by facilities. 
Table 6: Descriptive Analysis of Turnaround Time of Medicines to Health Facility 
 
                          TT (Days) 
 ------------------------------------------------------------- 
      Percentiles          Smallest 
  1%            0                 0 
  5%            0                 1 
 10%           .5                1       Obs            
10 
 
 25%            1               3       Sum of Wgt.         10 
  50%            7                      Mean           
11.4  
                      
                       Largest       Std. Dev.      14.92351 
75%           11              7 
 90%         38.5             11       Variance       222.7111 
95%           44             33       Skewness       1.414637 






Table 6 further illustrates the turnaround time of medicines to the health facility on receipt at 
CMS in the event they were out of stock.  The overall average mean was 11.4 days, the median 
was 7 days and the standard deviation was 14.9 days. 
 
4.8 SUMMARY 
This chapter presented a detailed analysis of the data and provided descriptive statistics of the 
study responses as they relate to the objectives and research questions. It showed the 
demographics of the patients interviewed and their socioeconomic status, presented their 
experiences with stock-outs of medicines at the health facility and the costs they incur when 
they buy the medicines from private pharmacies. It described the magnitude of the problem 
caused by non-communicable diseases and the challenges faced by patients affected by these 












CHAPTER 5: DISCUSSION 
 
5.1 INTRODUCTION 
This chapter presents a summary discussion of the findings. The discussion follows the themes 
outlined in chapter 4 in the results analysis and links the findings to the literature examined in 
chapter 2. Major findings are highlighted to be further summarized in chapter 6 when 
addressing implications and significance of this study. The first section of the chapter discusses 
the demographic information of the respondents, their socioeconomic status as well as their 
health profile and health seeking behavior.  The last section focuses of how the results 
corroborate existing literature regarding availability of medicines, doctor-patient relationships 
and patient direct costs of healthcare.   
 
5.2 DEMOGRAPHIC INFORMATION SUMMARY 
There seemed to be a significant variance between the male and female patient population at 
RFMH, with a high proportion of patients being the females (71%). These results were 
anticipated by the researcher as literature confirms high proportions of females at health 
facilities than males. This result seemed to match other studies as they showed that most 
females were affected by chronic conditions when compared to males (Hannan, 2009). This 
may also be due to the generally high rate of health seeking behavior among the female 
population (Knud and Kaare, 2005). In terms of age, the results showed that NCDs were highly 
prevalent for the age groups above 35 years. Older patients were the ones most affected by the 
chronic conditions between the ages 50 – 64 years (46%) as they accounted for almost half of 
the interviewed population. In addition, the results showed that a majority of the patients had 
received some basic education, (reached up to secondary level); however, there were a 
proportion of patients that had reached tertiary education. It was also quite significant that 
17% of the patients had never received any type education, hence were illiterate. This factor 
was posing a threat in terms of understanding issues in these patients when being educated 





5.3 SOCIOECONOMIC STATUS 
A significant proportion, approximately 60% of the patients at the facility were from the rural 
areas of Manzini region.  This means patients would travel for approximately 20 kilometers to 
access health care services. This calls for decentralization of NCD related health services to the 
rural areas of the country in general. In addition, almost half of the interviewed population 
(44%) earned a monthly income that is almost equivalent to less than US $50 which was way 
below gross national monthly income  per capita (USD233.33) of the country. According to 2010 
poverty world bank data, it showed that 40.6 % of the Swazi population was living below the 
poverty line of USD1.25 a day. This result confirmed the same findings of the World Bank data 
that these patients were living below the poverty line. In the face of catastrophic health 
expenditure, these patients were further impoverished by out-of pocket expenditure for their 
medicines. With this result, it showed that these patients would have to forgo other household 
necessities in order to access medications or health services to control their conditions. 
Although these patients were not asked how they were financing their health expenditure; a 
number of studies have shown that patients with chronic conditions will use a variety of ways 
to finance their health expenditure; some would sell their assets or borrow money (Van Damme 
et al., 2012). A majority of this population will tend to forgo the much needed care for their 
chronic conditions in the event of a stock out at the health facility because of financial 
constraints or will go into further financial catastrophe by borrowing money in order to buy 
medicines for their conditions out-of-pocket. The Bengal study in India also showed that the 
odds of incurring financial catastrophe for chronic conditions were greatest in out-patient care 







5.4 HEALTH STATUS AND HEALTH SEEKING BEHAVIOR 
The results showed that a high number of the interviewed patients were hypertensive followed 
by diabetes and asthma respectively. Eighty one percent of the patients honored their monthly 
appointments for refills of their medications, and these were mainly the diabetic and the 
hypertensive patients. . This showed a positive indication that these patients were educated by 
health professionals on the importance of monitoring their conditions and attending doctors’ 
appointments on monthly basis.  Asthma patients were the least to honor doctor’s 
appointments for refills as (58%) of them visited the facility only when feeling sick.   
 
5.5 AVAILABILITY OF MEDICINES 
A majority of the patients were not receiving all their prescribed medicines when visiting the 
facility and the main reason was stock outs. Although some patients were able to buy the out of 
stock medicines in private pharmacies immediately after leaving the facility, a significant 
number of these patients (60.4 %) could not because of limited financial resources. This 
unavailability of medicines exerts some financial pressure to the already impoverished patients 
and further distributes their household income share due to unanticipated health expenditure. 
This challenge will further increase the risk of patients not taking their prescribed medications 
for days and increase the risk of complications of their conditions. A number (25%) had 
reported hospitalization in the past six months because of their conditions. The consequence of 
disease complications will increase income loss due to inability to work to these patients. A 
study done among 875 adults with diabetes in the US in 2004 on problems paying out-of-pocket 
for their medication showed that medication costs posed significant problems on patients 





Medicine availability in health facilities plays a vital role in improving the chronic conditions of 
patients by improving their quality of life and having more controlled conditions with fewer 
complications that would need expensive interventions for treatment.  What further aggravates 
the challenge of medicine availability is the lack of any form of health insurance for a majority 
of the patients, (95%). For a majority of the patients, average medical costs incurred due to a 
stock out is approximately US $ 10, which is higher than the poverty line threshold of the 
country. Furthermore, the out-of-pocket amount spent in medicines by these patients due to 
unavailability at the facility showed to be between 10 times to 50 times more than the user 
fees (E10) charged to access health care services in any health facility in the country. This 
evidence shows a cause of concern for MOH to improve availability of medicines in health 
facilities in order to improve this financial catastrophe imposed to patients in the event of non-
availability of medicines. 
 
5.6 DOCTOR-PATIENT RELATIONSHIPS 
From the results we could conclude that counseling on medicines use was well established with 
patients as eighty percent reported that they were informed by the health practitioners on 
consequences of not taking medication as prescribed for their conditions. However, there 
seems to be lack of information given to patients on their rights and the extent to which they 
can express their views and challenges with regards to medicine availability as most of them 
felt they were not supposed to talk about issues of not being able to access the prescribed 
medicines because of lack of funds with the healthcare personnel. This situation is similar to the 
US study on problems of paying out-of-pocket for their medicines among diabetic patients, 
whereby patients were not comfortable in informing their clinicians that they could not afford 
to pay for their medications because they felt it would embarrass them (Piette et al., 2004). 
This study suggested that a collaborative communication with patients will assist in medication 
cost, adherence to treatment and improved health outcomes. Clinician-Patient communication 
should be strengthened in order achieve positive goals for health outcomes and improve 
quality of life of patients. A significant percentage (16%) of patients was admitted at least once 
in the past six months due to their conditions. This is a cause for concern for policy developers 
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as it evident that patients are not well controlled in their conditions and this may affect their 
health outcomes negatively. There will be loss of income due to hospital stay and increased 
out-of-pocket payment due to other costs related to admission. 
 
5.7 STOCK AVAILABILITY AT CENTRAL MEDICAL STORES 
The stock availability of the selected medicines at CMS varied per product. Some medicines 
were out of stock for a period of less than 30 days in a year (Captropril and Insulin Actrapahane) 
and some were out of stock for more than six months (Hydrochlorothiazide and Nifedipine Slow 
Release 20mg). This situation posed a financial threat to the patients using these medications 
and increased the risk of patients not taking their medication which would increase the risk of 
complications of their conditions. MOH should work on systems to improve availability of 
medicines in health facilities in order to provide financial protection to patients by reducing 
out-of-pocket expenditure for their medications and reduced complications from chronic 
conditions hence improved quality of life and economic situations.  The turnaround time of 
medicines on receipt at CMS to RFMH was within an acceptable period as it varied from 1day to 
30 days. This result showed that medicines were made available on time to the facility on 
receipt at CMS. This showed a good outcome in achieving some of the supply chain goals for 
MOH and good working relations between CMS and health facilities. 
 
5.8 SUMMARY 
This chapter presented a comprehensive discussion of the study findings and how they relate to 
the literature reviewed on the subject matter. It tied together all the chapters of the thesis and 






CHAPTER 6: CONCLUSION 
 
6.1 INTRODUCTION 
This chapter presents the conclusions of the study based on the findings. Also presented in this 
chapter are the study limitations, recommendations as well as the significance of the study to 
the country’s health authorities, research institutions and general population.  
 
6.2 STUDY LIMITATIONS 
The following were the major limitations of the study; 
1. Study setting not representative: Because patients interviewed were from one facility in 
one region there is limited generalizability of the findings to other parts of the country. 
2. Costs to patients not exhaustive: While the direct out-of-pocket costs of buying the 
medicines could be established, these were a small fraction of the total costs incurred by 
patients and their families in their efforts to access treatment for their conditions.  
 
6.3 RECOMMENDATIONS 
Based on the findings analyzed in chapter 4 and further discussed in chapter 5 the following 
recommendations are made; 
1. MOH policy developers should review current pharmaceutical policy to accommodate 
strategies by which to improve access to health care and medicines for patients with 
chronic conditions.  
2. Policies used to treat communicable and transmittable diseases should be implemented at 
small scale for NCD’s to assess its impact in improving availability of medicines for non -
communicable conditions in health facilities 
3. Ministry of Health should develop a framework for regulating medicine prices both in 
private and public sector in order to reduce the financial burden borne by patients when 
buying medicines from private pharmacies. 
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4. Further research on coping strategies for patients with NCD’s should be conducted on a 
larger population of the country in order to ascertain how patients are coping with the 
burden of out-of-pocket expenditure when accessing healthcare services. 
 
6.4 SIGNIFICANCE OF THE STUDY 
This study reinforced the role of the first Standard Treatment Guidelines and Essential 
Medicines Lists launched in 2012 in regulating prescription of medicines and ensuring 
availability of essential medicines in the country. Moreover, the study highlighted the current 
gaps especially at the central medical stores that directly result in stock-out of chronic 
conditions medicines in public health facilities. This is a new body of knowledge that would help 
the Ministry of Health develop evidence based strategies to improve medicines supply chain 
management system in the country.    
 
6.5 CONCLUSION 
The MOH is depending on user fees from patients for health care financing mechanisms. Many 
families in the country could find this a challenge, as 63% of the country’s population already 
lives below the poverty line. MOH policy developers should review how best access to health 
care can be improved and availability of medicines for chronic conditions in healthcare facilities 
in order to provide financial protection to patients. The issue of paying user fees for patients 
with chronic conditions to access healthcare services should also be reviewed by policy 
developers as some patients with chronic conditions will not access healthcare when not 
feeling sick because of financial limitations whilst increasing the risk of complications from their 
conditions. Policies used to treat communicable and transmittable diseases should be 
implemented at small scale for NCD’s to assess its impact in improving availability of medicines 
for non -communicable conditions in health facilities of Swaziland. 
 
Results in this study have shown that patients averagely were paying 10 times to 50 times more 
to access medicines for their conditions in private pharmacies than when they were accessing 
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them in a public health facility. This brings more financial constraints to the patients and can 
cause a lot of incompliance to treatment and more complications of their conditions which are 
more expensive to treat. This situation calls for urgent attention for the Ministry of Health to 
work on the issue of medicines price regulation in order to reduce the challenges by having 
affordable medicines whether in public or private health facilities and a strong drug policy to 
strengthen availability of essential medicines in health facilities.  
 
MOH achieved one of its Pharmaceutical Strategic Plan goals by having the first Standard 
Treatment Guidelines and Essential Medicines Lists launched in 2012. In order to achieve safe 
prescribing and availability of medicines in health facilities, MOH has to enforce prescribing 
using the STG’s by prescribers and availability of medicines listed in the EML in all health 
facilities by having a drug policy that will enforce procurement of quality medicines according 
to the EML. This has been evident to improve availability of medicines in health facilities and 
provide good management of chronic conditions, reduce complications of diseases in patients 
in other low income countries like India (Chaudhury et al., 2005). This study also showed 
improved availability of essential medicines at facilities, though not 100% availability at all 
times. The stock out periods needs to be addressed at CMS level. Further investigation is 
required as to whether this is an issue of financial resources or poor logistics skills. 
 
95% of the interviewed patients had no health insurance to pay for their medicines in the event 
their medicines were out of stock in the facility. The MOH should also look into issues of 
financing healthcare with a form of health insurance for certain conditions and certain age 
groups in order to reduce catastrophic situations, morbidity and mortality and improve the 
quality of life of the country population. 
 
Research on coping strategies for patients with NCD’s should be further done on a larger 
population of the country in order to have access to more information on how these patients 
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are coping with the burden of out-of-pocket expenditure on medicines for their conditions, how 
they finance the out-of-pocket expenditure and necessities they end up losing in efforts to 
access medicines for their health conditions. This will assist MOH policy developers to do a 
good analysis of the situation and develop finance mechanisms that will improve access to 
health care for patients and a strong drug policy to improve medicine availability in public 
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ANNEXURE 1: PATIENT QUESTIONNAIRE 
 
Questionnaire Forms: Coding Sheet 
Name of Hospital….. Raleigh Fitkin Memorial Hospital 
(9999 is for missing data) 
 
SECTION A: DEMOGRAPHIC CHARACTERISTICS  
 
1. Age……………. (years)  
                18 – 24 = 1 
                25 -34                = 2 
                35 – 49 = 3 
                50 – 64 = 4 
                65+  = 5 
                Declined to answer  9999 
 
2. Gender 
             Male  = 1 
             Female                = 2 
 
3. Educational level:    
            Primary level    = 1 
            Secondary level               = 2 
            Tertiary level  = 3 
             Never                    = 4 
 
4. Marital status:          
            Single                         = 1 
            Married                      = 2 
            Divorced                    = 3 
            Widowed                   = 4 
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5. Occupation:   
             Unemployed             = 1 
             Employed                 = 2 
             Self Employed          = 3 
             Pensioned                 = 4 
 
6.        Religion:    
            Christianity               = 1 
            Muslim                     = 2 
            Hindu                        = 3 
            Other………..             = 4 
 
SECTION B: SOCIO ECONOMIC STATUS (SE) 
 
1. Area of Residence:    
             Urban                = 1 
             Rural                 = 2 
            Semi – Urban     = 3 
 
2. Monthly income (family):      
             < E500                  = 1 
             E501-E1000         = 2 
             E1001-E2000       = 3 
             E2001 – E5000    = 4 












SECTION C: HEALTH STATUS OF CLIENT: (HS) 
 
1. What condition have you been diagnosed with? 
 Hypertension      = 1 
 Asthma               = 2 
 Diabetes              = 3 
 Other                   = 4 
2. How long have you been diagnosed with your condition? 
             6 months – 1 year    = 1 
             1 year – 2 years       = 2 
             ≥ 2 years                   = 3 
 
3.          How often do you come to this facility to refill your medications? 
             Every month                     = 1 
             Once in 2 months             = 2 
             Only when feeling sick     = 3 
 
4.       If they answer once in 2 months or when feeling sick ask that: 
What are the contributing factors that make you to come in these intervals as your condition needs to 
be reviewed every month? 
           
          Money for transport to the facility                              = 1 
          I do not see the reason to come every month            = 2 
          No one told me to come on a monthly basis               = 3 












SECTION D: AVAILABILITY OF MEDICINES IN THE DISPENSARY (AMD) 
 
1. When coming to collect your monthly medications in the pharmacy do you always get all the 
prescribed medicines? 
 Yes                               = 1 
              No                                 = 2 
              Sometimes                  = 3 
 
2. How many times in the past 6 months when coming to collect your medications in the 
dispensary you did not get everything that was prescribed by the doctor? 
 Once                                     = 1 
             Two times                              = 2 
              More than three times       = 3 
              Not sure                                 = 4 
3. How many times in the past 6 months did you come back to the facility and still find that the 
same medication/s is still out of stock? 
 Once                                      = 1      
             Two times                               = 2 
             More than three times         = 3 
              Not sure                                 = 4 
 
4. (a) Did you receive all your prescribed medications today? 
                  Yes                = 1 
                   No                 = 2 
4. (b)  
Check and list the medication the patient received versus prescribed. Calculate the percentage of 
medicines received today. 
--------------------------------                        --------------------------------------------- 
----------------------------------                     ---------------------------------------------- 
---------------------------------                     ---------------------------------------------- 







5. What did the dispensing personnel explain to you about the medicine/s that    
is / are not available in the dispensary? 
            To return to the doctor to be given another medication             = 1 
             To go and buy the medicine in the chemist                                   = 2 
 
6. In the event you have to go and buy the medication in the chemist, how soon do you buy your 
medication? 
              As soon as I leave the facility                                                                            = 1 
             Whenever after getting money                                                                         = 2 
              When I go to town as there are no chemists close to the community      = 3 
              When I get paid                                                                                                   = 4 
              When I feel sick                                                                                                   = 5 
 
7. On average, how much has your medication cost you when you buy it at the chemist in the 
event it is out of stock in the facility in the past 6 months? 
               Less than E100                     = 1 
              Between E100 – 300             = 2 
              Between E301 – E500           = 3 
              Above E500                            = 4 
8. Do you have a healthcare insurance cover that you use to buy your medication with incase it is 
out of stock in the facility? 
               Yes   = 1 
               No    = 2 
 
9. How much do you pay averagely per month for your health insurance cover? 
             Less than E1000                                                               = 1 
             More than E1000                                                            = 2 
             Not Sure, because it is paid by spouse/family           = 3 
             Not applicable                                                                  = 4 






10. Do you or your family buy medicines for other members of your family? If so, how many? 
1                              = 1 
               2                              = 2 
              3                               = 3 
            More than 5            = 4 
            None                       = 5 
 
11. Anything that you would like to add on the issue of the cost of your medication that are not 




 SECTION E: PATIENT - DOCTOR OR HEALTH PERSONNEL COMMUNICATION: (COMM) 
 
1. Has the doctor, nurse or dispensing personnel explained to you the consequences of not taking 
your medication regularly. 
                    Yes             = 1 
                    No               = 2 
 
2. Have you been hospitalized because of not taking your medication due to out of stock of your 
medication in the facility or not affording to buy the medication out-of-pocket in the past 6 
months? 
                   Yes              = 1 
                   No                = 2 
 
3. If yes, for how long were you hospitalized? 
                   < 3 days                            = 1 
                    ≥ 3 days                           = 2 
                   Other -----------------         = 3 
4. Have you ever missed coming to the health facilities for your appointments due to lack of funds? 
                  Yes    = 1 






5. After the health personnel has told you to buy your out of stock medication in the chemist, have 
you ever told her/him that you cannot afford to buy the medication because of limited funds 
and if no, why not? 
               Yes                                                                                                                   =1 
               No, because I thought that there is nothing that he/she can do         = 2  
               No, because I felt it will embarrass me                                                     = 3 
                No, because I felt it was unnecessary                                                        = 4 
              























ANNEXURE 2: CENTRAL MEDICAL STORES DATA COLLECTION SHEET 
 
The medicines to be used for data collection from Central Medical Stores has been chosen based on the 
fact that these are medicines in the Swaziland Essential Medicines List and Standard Treatment 
Guidelines that are currently part of the treatment used for the three selected conditions (hypertension, 
diabetes and asthma). 
Medication: How many days has each of these medications been out of stock in the past 12 months? 
What has been its turnaround time to the facility (RFM hospital) from the date of receipt at CMS? 
(a) Captopril 25mg tablets 
Days Out of Stock 
___________ Days 
Turnaround time to facility after date of receipt 
________ Days 
__________   Months 
 
(b) Hydrochlorothiazide 25mg tablets 
Days Out of Stock 
    __________ Days 
Turnaround time to facility after date of receipt 
__________ Days 
__________   Months 
(c) Enalapril 20mg tablets 
Days Out of Stock 
   __________ Days 
Turnaround time to facility after date of receipt 
_________ Days 




(d) Glibenclamide 5mg tablets 
Days Out of Stock 
__________ Days 
Turnaround time to facility after date of receipt 
_________ Days 
__________   Months 
(e) Metformin 500mg tablets 
Days Out of Stock 
__________ Days 
Turnaround time to facility after date of receipt 
________ Days 
__________   Months 
(f) Insulin (Actraphane)   
Days Out of Stock 
__________ Days 
Turnaround time to facility after date of receipt 
_________ Days 
__________   Months 
 
(g) Salbutamol spray:  
Days Out of Stock  ________ Days 
Turnaround time to facility after date of receipt 
_________ Days 
__________   Months 
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(h) Beclomethasone spray 
Days Out of Stock 
___________ Days 
Turnaround time to facility after date of receipt 
_______ Days 
__________   Months 
(i) Salbutamol 4mg tablets 
Days Out of Stock 
__________ Days 
Turnaround time to facility after date of receipt 
__________ Days 
__________   Months 
(j) Nifedipine 20mg slow release tablets 
Days Out of Stock 
_________ Days 
Turnaround time to facility after date of receipt 
________ Days 

















Captopril 25 mg tablets 1 1
Hydrochlorthiazide 25 mg tablets 5 9999
Enalapril 20 mg tablets 2 1
Nifedipine Slow Release 20 mg tablets 5 1
Glibenclamide 5 mg tablets 3 2
Metformin 500 mg tablets 2 1
Insulin -Actraphane 1 1
Salbutamol 4 mg tablets 4 1
Salbutamol  spray 2 2
Beclomethasone spray 3 1
OS - for Out Of Stock






































I ................................................................................................ (full names of participant) hereby confirm 
that I understand the contents of this document and the nature of the research project, and I consent to 
participating in the research project. I was given the opportunity to ask questions and clarification was 
given to my satisfaction. I also understand that my participation is completely voluntary, that I reserve 
the right to withdraw from participating any time I feel like. I understand that I was provided the choice 
to have the interview recorded or not. 
 
 
SIGNATURE OF PARTICIPANT                                                 DATE 
 
............................................................................................................................................. 
 
 
 
 
 
 
 
 
 
 
 
 
